Literature DB >> 6183482

Interactions of diuretics with the renal kallikrein-kinin and prostaglandin systems.

A Overlack, K O Stumpe, H M Müller, R Kolloch, M Higuchi.   

Abstract

The renal kallikrein-kinin system may participate in the diuretic, natriuretic and antihypertensive effect of diuretics. This possibility was investigated by studying the influence of hydrochlorothiazide on blood pressure and urinary kallikrein excretion in patients with essential hypertension. Furthermore, the effect of kallikrein-blockade and prostaglandin-synthesis inhibition on the acute furosemide-induced changes of diuresis, natriuresis, GFR and renal plasma flow were studied in normotensive subjects. Thiazide treatment normalized the reduced kallikrein excretion of the hypertensive patients. The fall in mean arterial blood pressure was significantly correlated with the increase in urinary kallikrein excretion. In the normotensive subjects aprotinin-induced kallikrein inhibition failed to alter the acute response to furosemide, whereas indomethacin attenuated the diuretic and natriuretic effect of furosemide. The combination of indomethacin and aprotinin had a greater suppressive effect on plasma renin activity than indomethacin alone, suggesting a participation of kallikrein in renin release. An increase in the activity of the renal kallikrein-kinin system may contribute to the long-term antihypertensive effect of thiazide diuretics but it does not seem to be involved in the acute renal responses to furosemide.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6183482     DOI: 10.1007/bf01716727

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  36 in total

1.  EFFECT OF BRADYKININ ON RENAL FUNCTION.

Authors:  M A BARRACLOUGH; I H MILLS
Journal:  Clin Sci       Date:  1965-02       Impact factor: 6.124

2.  THE MEASUREMENT OF THE TUBULAR EXCRETORY MASS, EFFECTIVE BLOOD FLOW AND FILTRATION RATE IN THE NORMAL HUMAN KIDNEY.

Authors:  H W Smith; W Goldring; H Chasis
Journal:  J Clin Invest       Date:  1938-05       Impact factor: 14.808

3.  Bumetanide induced increase of renal blood flow in conscious dogs and its relation to local renal hormones (PGE, kallikrein and renin).

Authors:  U B Olsen; I Ahnfelt-Ronne
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976-03

4.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

5.  Mechanism of natriuretic action of bradykinin.

Authors:  L R Willis; J H Ludens; J B Hook; H E Williamson
Journal:  Am J Physiol       Date:  1969-07

6.  Effect of captopril and aprotinin on inactive renin.

Authors:  J E Sealey; A Overlack; J H Laragh; K O Stumpe; S A Atlas
Journal:  J Clin Endocrinol Metab       Date:  1981-09       Impact factor: 5.958

Review 7.  The renal kallikrein-kinin system.

Authors:  O A Carretero; A G Scicli
Journal:  Am J Physiol       Date:  1980-04

8.  Drugs which inhibit prostaglandin biosynthesis.

Authors:  R J Flower
Journal:  Pharmacol Rev       Date:  1974-03       Impact factor: 25.468

9.  Decreased urinary kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension.

Authors:  A Overlack; K O Stumpe; C Ressel; R Kolloch; W Zywzok; F Krück
Journal:  Klin Wochenschr       Date:  1980-01-02

10.  Radioimmunoassay of prostaglandins Falpha, E1 and E2 in human plasma.

Authors:  F Dray; B Charbonnel; J Maclouf
Journal:  Eur J Clin Invest       Date:  1975-07-29       Impact factor: 4.686

View more
  2 in total

Review 1.  Clinical application of inhibitors of fibrinolysis.

Authors:  M Verstraete
Journal:  Drugs       Date:  1985-03       Impact factor: 9.546

2.  Role of protease-activated receptor 2 in regulation of renin synthesis and secretion in mice.

Authors:  Lena R Thurner; Klaus Höcherl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-06-27       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.